Lannett enters licensing agreement for generic concerta, methylphenidate hydrochloride ER tablets

Lannett Company, Inc. announced that it has entered into an exclusive perpetual licensing agreement with Andor Pharmaceuticals, LLC for Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths.

New supporting programs at analytica Anacon India and India Lab Expo this year in Hyderabad

More than 300 companies will be exhibiting at India's leading trade fair for laboratory technology, analysis, biotechnology and diagnostics industry displaying the best of the technologies.

Titan Announces Amendment To Agreement With Molteni

Titan Pharmaceuticals, Inc. announced that it has entered into an amendment of the previously announced definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Societa di Esercizio S.p.A. through which Molteni acquired the EU intellectual...

Celtaxsys announces results of phase 2 trial showing clinically meaningful improvement in pulmonary exacerbations in cystic fibrosis patients

Celtaxsys, Inc announced top line results of its Phase 2 EMPIRE-CF trial evaluating oral, once daily anti-inflammatory molecule, acebilustat, for the treatment of cystic fibrosis , irrespective of the causative...

Get ready to witness the best of pharmaceutical machinery and allied technologies in Hyderabad

Under the new management of Messe Muenchen India, the leading exhibition on pharma processing & packaging machineries – PHARMA Pro & Pack 2018 is expected to feature over 100 exhibitors & attract more...

Albumedix announces evaluation agreementwith a top pharma collaborator

Novartis and Albumedix Ltd. have entered into an agreement to evaluate the development of several first -in-class therapeutics using Albumedix's Veltis technology platform and associated technologies.

For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
or
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2018 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com